Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review

INTRODUCTION: HTX-019 [CINVANTI(®) (aprepitant injectable emulsion)] is a neurokinin 1 receptor antagonist (NK-1 RA) approved as a 30-min infusion for preventing acute and delayed chemotherapy-induced nausea and vomiting. HTX-019 has been generally well tolerated when administered as a 30-min infusi...

Descripción completa

Detalles Bibliográficos
Autor principal: Walton, Gary D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824338/
https://www.ncbi.nlm.nih.gov/pubmed/30706408
http://dx.doi.org/10.1007/s12325-019-0877-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824338/
https://www.ncbi.nlm.nih.gov/pubmed/30706408
http://dx.doi.org/10.1007/s12325-019-0877-3

Ejemplares similares